Pediatric blood cell transplantation.

Semin Oncol Nurs

Children's Hospital of Orange County, CA, USA.

Published: August 1997

AI Article Synopsis

  • The review focuses on blood cell transplantation (BCT) in children, discussing its uses, psychological and developmental challenges, and supportive care guidelines.
  • BCT is deemed a safe and effective option for pediatric patients facing serious conditions like disseminated disease or relapse after chemotherapy.
  • Pediatric oncology nurses play a crucial role in the care team, emphasizing the need for careful monitoring, supportive care, and complication management for successful recovery.

Article Abstract

Objectives: To provide a review of the use of blood cell transplantation (BCT) in pediatric patients, the psychological and developmental issues related to BCT, and guidelines for supportive care.

Data Sources: Review articles, research studies, and book chapters pertaining to BCT in children with cancer.

Conclusions: BCT is a safe and reliable source of support after myeloablative regimens for children with disseminated disease, relapse or failure after chemotherapy, or children with high-risk features at diagnosis.

Implications For Nursing Practice: The pediatric oncology nurse is an integral part of the multidisciplinary team in providing long-term care for children undergoing BCT. Astute clinical monitoring, supportive care, and management of complications is of utmost importance to recovery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0749-2081(97)80034-4DOI Listing

Publication Analysis

Top Keywords

blood cell
8
cell transplantation
8
bct
5
pediatric blood
4
transplantation objectives
4
objectives provide
4
provide review
4
review blood
4
transplantation bct
4
bct pediatric
4

Similar Publications

In this study, we first analyzed data from 147 patients with solitary plasmacytomas treated at the Mayo Clinic between 2005 and 2022 and then expanded our investigation through a systematic review and meta-analysis of 62 studies, encompassing 3,487 patients from the years 1960 to 2022. Our findings reveal that patients with up to 10% clonal plasma cells in their bone marrow (BM), denoted as plasmacytoma +, had a significantly reduced median disease-free survival (DFS) of 15.7 months vs.

View Article and Find Full Text PDF

Chimeric antigen receptor (CAR) T-cell products axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel) are approved for relapsed/refractory large B-cell lymphoma (R/R LBCL). Emerging evidence indicates that delayed CAR T-cell infusion, including prolonged time from leukapheresis to infusion, known as vein-to-vein time (V2Vt), may adversely impact clinical outcomes. We conducted a systematic literature review (SLR) and meta-analysis to identify differences in V2Vt in patients with R/R LBCL treated with axi-cel, tisa-cel, or liso-cel.

View Article and Find Full Text PDF

Background: Gastrointestinal bleeding (GIB) is a severe and potentially life-threatening complication in patients with acute myocardial infarction (AMI), significantly affecting prognosis during hospitalization. Early identification of high-risk patients is essential to reduce complications, improve outcomes, and guide clinical decision-making.

Objective: This study aimed to develop and validate a machine learning (ML)-based model for predicting in-hospital GIB in patients with AMI, identify key risk factors, and evaluate the clinical applicability of the model for risk stratification and decision support.

View Article and Find Full Text PDF

Purpose: Asparaginase (ASN) is a critical component of pediatric ALL protocols. Until recently, ASN was available in three formulations: native Escherichia coli, PEGylated E. coli (PEG), and Erwinase, with native E.

View Article and Find Full Text PDF

The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in bladder cancer. The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least testing to help facilitate the selection of future therapeutic options. Sequencing of tumor-derived tissue is the mainstay to obtain this genomic testing, but as in other cancers, there has been extensive research into the integration of liquid biopsies in longitudinal management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!